Active Filter(s):
Details:
These funds will support advancing the Company’s first product, PCLX-001, to clinical trials anticipated to start later this year.
Lead Product(s): PCLX-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Canadian angel investors
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Financing March 04, 2020